迪安诊断技术集团股份有限公司（以下简称"公司"）董事会近日收到公司 董事洪汉华先生的书面辞职报告，洪汉华先生因个人原因，申请辞去公司第五届 董事会董事、董事会专门委员会委员及公司副总经理的职务，辞职后不再担任公 司任何职务。洪汉华先生的辞职不会导致公司董事会人数低于法定人数，其辞职 报告自送达公司董事会之日起生效，不会影响公司董事会正常运行。公司将尽快 按照相关规定完成董事补选工作。 洪汉华先生原定第五届董事任期为 2023 年 11 月 3 日至 2026 年 11 月 3 日。 截至本公告披露日，洪汉华先生未持有公司股份，不存在应当履行而未履行的承 诺事项。 洪汉华先生离任后将继续遵守《上市公司董事、监事和高级管理人员所持本 公司股份及其变动管理规则》《上市公司股东、董监高减持股份的若干规定》等 相关法律、法规、规范性文件及其作出的相关承诺，在原定任期内届满之日以及 届满后 6 个月内遵守下述规定： 1、每年转让的股份不得超过其所持有本公司股份总数的 25%； 2、离职后半年内，不得转让其所持本公司股份； 证券代码：300244 证券简称：迪安诊断 公告编号：2025-033 迪安诊断技术集团股份有限公司 ...

证券日报网讯迪安诊断（300244）9月30日在互动平台回答投资者提问时表示，在通用大模型的整合 上，公司始终保持开放和敏捷的态度。目前，公司自研模型已成功接入并应用了包括ChatGPT、 DeepSeek、通义千问在内的多家领先模型，并根据不同业务场景的需求进行了优化配置。对于任何新 发布的模型，公司的技术团队都会在第一时间进行专业的评估与测试，并择优接入。 ...

Group 1 - The Fourth Global Digital Trade Expo opened in Hangzhou, where Dean Diagnostics signed a strategic cooperation agreement with Hangzhou Data Group to co-build a trusted data space for the city [1] - The collaboration aims to create advanced and secure infrastructure for the trusted data space, explore market-oriented data allocation mechanisms, and promote efficient data circulation to enhance the regional digital economy [1][2] - Dean Diagnostics will leverage its high-quality data resources in the medical diagnostics field to establish a trusted data sub-space for the industry, facilitating compliant data circulation and commercial applications [1][2] Group 2 - Dean Diagnostics has developed high-quality data sets across various fields, including oncology, infections, chronic diseases, and maternal and child health, based on over 20 years of service to more than 22,000 medical institutions [2] - The company plans to transition from a data provider to a data operator and value co-creator, establishing a closed-loop ecosystem of "data-service-application" [2] - The launch of the "Smart Inspection Link - Integrated Management Platform for Regional Testing/Pathology" aims to address challenges in regional healthcare, enhancing digital capabilities in grassroots medical services [3]

Core Viewpoint - The strategic partnership between Dian Diagnostics and Hangzhou Data Group aims to establish a trusted data space in Hangzhou, focusing on the efficient circulation of data elements and promoting high-quality development of the regional digital economy [1][2]. Group 1: Strategic Collaboration - Dian Diagnostics signed a strategic cooperation agreement with Hangzhou Data Group to co-build a trusted data space infrastructure in Hangzhou [1]. - The collaboration will leverage Dian Diagnostics' extensive medical testing data to create a compliant trading platform for medical data elements [2]. - The partnership aims to develop high-quality medical data sets and AI medical products, enhancing public health monitoring services for government departments [2]. Group 2: Data Utilization and Innovation - Dian Diagnostics plans to transition from a data provider to a data operator and service enabler, creating a closed-loop ecosystem of "data-service-application" [3]. - The company will enhance AI model optimization in areas such as auxiliary diagnosis and health management through deep operation of medical data assets [3]. - The initiative aims to integrate medical data with digital technology and public services, contributing to Hangzhou's goal of becoming a "digital health capital" [3].

Group 1 - The core viewpoint of the news is that Dian Diagnostics has experienced a decline in stock price recently despite a significant increase in its stock price year-to-date, indicating potential volatility in the market [1][2]. - As of September 16, Dian Diagnostics' stock price was 17.02 yuan per share, with a market capitalization of 10.637 billion yuan and a trading volume of 1.21 billion yuan [1]. - The company has seen a year-to-date stock price increase of 53.25%, but it has experienced a slight decline of 1.45% over the last five trading days [1]. Group 2 - Dian Diagnostics operates in the pharmaceutical and biological industry, specifically in medical services and diagnostic services, and is associated with several concept sectors including Huawei and Alibaba [2]. - For the first half of 2025, Dian Diagnostics reported a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61%, and a net profit of 10.2772 million yuan, down 85.68% compared to the previous year [2]. - The company has distributed a total of 1.099 billion yuan in dividends since its A-share listing, with 712 million yuan distributed over the past three years [3]. Group 3 - As of June 30, 2025, the number of shareholders for Dian Diagnostics was 48,300, a decrease of 11.32% from the previous period, while the average number of circulating shares per person increased by 12.77% to 10,376 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder, increasing its holdings by 3.4713 million shares [3]. - The company has seen changes in institutional holdings, with some funds increasing their positions while others have exited the top ten shareholders list [3].

Core Insights - On September 9, 2023, Dian Diagnostics experienced a decline of 2.92% in stock price, with a trading volume of 409 million yuan [1] - The company reported a net financing outflow of 13.31 million yuan on the same day, with a total financing and securities balance of 684 million yuan [1][2] - For the first half of 2025, Dian Diagnostics achieved a revenue of 4.936 billion yuan, a year-on-year decrease of 20.61%, and a net profit of 10.277 million yuan, down 85.68% year-on-year [2] Financing and Securities - On September 9, 2023, Dian Diagnostics had a financing buy-in of 35.955 million yuan, with a current financing balance of 6.82 billion yuan, representing 6.31% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had a securities lending balance of 2.0534 million yuan, with a lending volume of 118,900 shares on the same day [1] Shareholder Structure - As of June 30, 2025, the number of shareholders for Dian Diagnostics was 48,300, a decrease of 11.32% from the previous period [2] - The average number of circulating shares per person increased by 12.77% to 10,376 shares [2] - Major shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 3.4713 million shares, and a new shareholder,招商优势企业混合A, holding 11 million shares [3]

Market Overview - The medical services sector rose by 3.64% on August 29, with the leading stock being Puris [1] - The Shanghai Composite Index closed at 3857.93, up 0.37%, while the Shenzhen Component Index closed at 12696.15, up 0.99% [1] Top Gainers in Medical Services - Zenggansi (301257) closed at 43.54, up 20.01% with a trading volume of 64,900 shares and a turnover of 278 million [1] - Haoyuan Pharmaceutical (688131) closed at 68.48, up 13.70% with a trading volume of 189,200 shares and a turnover of 1.256 billion [1] - Bidai Pharmaceutical (688073) closed at 67.11, up 10.43% with a trading volume of 28,300 shares and a turnover of 182 million [1] - Meidi Xi (688202) closed at 64.21, up 8.96% with a trading volume of 124,400 shares and a turnover of 784 million [1] - WuXi AppTec (603259) closed at 103.30, up 7.95% with a trading volume of 1,016,600 shares and a turnover of 10.18 billion [1] Top Losers in Medical Services - Digital Human (835670) closed at 17.54, down 6.20% with a trading volume of 127,200 shares and a turnover of 227 million [2] - Puri Eye Hospital (301239) closed at 40.78, down 4.63% with a trading volume of 49,600 shares and a turnover of 203 million [2] - Yingkang Life (300143) closed at 10.64, down 3.45% with a trading volume of 230,300 shares and a turnover of 250 million [2] Capital Flow in Medical Services - The medical services sector saw a net inflow of 1.259 billion from institutional investors, while retail investors experienced a net outflow of 446 million [2][3] - Major stocks like WuXi AppTec had a net inflow of 1.269 billion from institutional investors, while it faced a net outflow of 741 million from retail investors [3]

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 18.40 CNY, based on a 23x PE for 2026 [2][5]. Core Views - The company is experiencing short-term pressure on performance, but its ICL business is showing stable growth. The revenue for the first half of 2025 was 4.94 billion CNY, down 20.6% year-on-year, while the net profit attributable to the parent company was 0.1 billion CNY, down 85.7% year-on-year [10]. - The ICL business structure is being optimized, and the strategic transformation towards IVD is accelerating. The revenue from ICL in the first half of 2025 was 1.63 billion CNY, down 25.6% year-on-year, with a significant improvement in the business structure [10]. - The company is actively pursuing overseas business opportunities and has established a new growth curve through "AI + Data" initiatives. The company has received ISO 15189 and EQA certifications for its Vietnam operations, enhancing its recognition in the local healthcare system [10]. Financial Summary - The company's revenue is projected to be 12.231 billion CNY in 2025, with a slight increase of 0.3% year-on-year. The operating profit is expected to recover significantly to 0.247 billion CNY, reflecting a growth of 892.3% year-on-year [4][12]. - The net profit attributable to the parent company is forecasted to be 0.146 billion CNY in 2025, showing a year-on-year increase of 140.8% [4][12]. - The earnings per share (EPS) is expected to be 0.23 CNY in 2025, with projections of 0.80 CNY and 1.00 CNY for 2026 and 2027, respectively [2][4].

Core Viewpoint - The company is undergoing significant transformation and growth, driven by strategic initiatives and market dynamics, while addressing challenges posed by industry policies and competition [2][4]. Industry and Company Development Trends - The company has eliminated goodwill and COVID-19 related reporting interference, leading to a critical period for increasing market concentration among leading firms as the industry accelerates the exit of smaller players [2]. - Despite pressures from policies like DRG and centralized procurement, these have also catalyzed the company's business and product structure transformation, enhancing market share through a "product + service + digitalization" model [2]. Five-Year Strategic Plan and Half-Year Performance - Cost Control: The company achieved over a 25% reduction in procurement costs, with management and financial expenses decreasing by 16% and 29% year-on-year, respectively [3]. - Technical Competitiveness: Key business areas such as pathogen tNGS, hematology, and tumor companion diagnostics grew by 35%, 22%, and 20%, respectively, with special inspection revenue now accounting for 47.63% of diagnostic service revenue, up 7.32 percentage points from the end of 2024 [3]. - Development of Proprietary Products: The Kai Le Pu reagent consumables business grew by 43%, and the company has integrated smart products into its core strategy, launching a three-year plan for medical AI [3]. - Customer Structure Optimization: The company signed 1,036 new clients, including 133 tertiary hospitals, with revenue from tertiary hospitals now making up 49.28% of total revenue, an increase of 6.46 percentage points from the end of 2024 [3]. - Internationalization Progress: The company’s Vietnam branch received ISO15189 certification and is actively expanding into the "Belt and Road" markets, collaborating with domestic IVD companies to develop business in the Middle East [3]. Investor Inquiry Response Highlights - Impact of Package Splitting Policy: The company is enhancing competitiveness through regional integration and cost reduction, aiming to maintain stable gross margins and expand market share [4]. - Accounts Receivable and Cash Flow: The company expects better cash flow from regular business in the second half of the year, with COVID-19 related receivables anticipated to be fully accounted for by year-end [4]. - Development of Technical Talent: The company is advancing discipline construction and talent acquisition, having introduced 107 new testing projects and initiated a training program for commercial talent [4]. - Market Share and Precision Centers: The company is rapidly increasing market share, with 61 precision centers now profitable, and expects a doubling of revenue from precision centers by year-end compared to the previous year [4]. - Smart Product Advantages and Planning: The company’s smart product revenue has already surpassed the total for the previous year, with plans for product pipeline updates in the second half [4]. - Service Gross Margin Improvement: The service gross margin has increased by 0.8 percentage points year-on-year, with expectations for this trend to continue [4]. - Data Asset Value: The company conducts approximately 160 million tests annually, accumulating over 20PB of data, which can be utilized for research, AI training, and customer data services [4]. - Outbound Planning Progress: The company is promoting its services and products internationally through a "product + service + digitalization" approach, leveraging the "Belt and Road" initiative [4].

Group 1: Current Development Trends - The company has gradually cleared goodwill and interference from COVID-19 related reports, laying a foundation for future growth [1] - The industry is accelerating the exit of "small and scattered" enterprises, entering a critical period for leading companies [1] - Despite pressures from policies like DRG and centralized procurement, the company is transforming its organizational, business, and product structures [1] Group 2: Five-Year Strategic Plan and Progress - The company aims to enhance internal management and focus on high-quality development, achieving over 25% reduction in procurement costs and 16% and 29% decreases in management and financial expenses respectively [2] - Core technology competitiveness in blood, neuroimmunology, and pathology has been strengthened, with pathogen tNGS, liquid biopsy, and tumor companion diagnostics growing by 35%, 22%, and 20% respectively [2] - The proportion of special testing revenue in diagnostic service revenue has increased to 47.63%, up by 7.32 percentage points from the end of 2024 [2] Group 3: Customer and Market Expansion - The company signed 1,036 new clients in the first half of 2025, with 133 being tertiary hospitals, increasing the revenue share from tertiary hospitals to 49.28% [2] - Cumulative cooperative clients exceed 800, with nearly 100 precision centers established [2] - The company is actively exploring international markets, with Vietnam's lab receiving ISO 15189 certification [2] Group 4: Financial Performance and Cash Flow - Accounts receivable reached 5.383 billion yuan, with a provision of 215 million yuan, indicating an expected improvement in cash flow management [4] - Operating cash flow improved to 278 million yuan, a 199.56% increase compared to the same period in 2024 [4] Group 5: Service and Product Innovations - The company has launched a digital product matrix including data, AI+CDSS, AI+health management, and AI+CRO, with revenue from digital products surpassing the total for the previous year [9] - The gross profit margin for services increased by 0.8 percentage points to 33.12%, attributed to strategic adjustments and optimization of customer structure [10] Group 6: Industry Challenges and Responses - The impact of the Jiangsu province tumor gene testing centralized procurement policy is expected to lower prices significantly, but the company anticipates long-term growth due to its integrated advantages [11] - The company is transitioning from traditional hospital collaborations to a networked service system, enhancing service offerings from diagnosis to full lifecycle management [12] Group 7: Data Utilization and Future Plans - The company has accumulated over 20 PB of data, with annual increments of approximately 1.5 PB, which will be utilized for AI model training and clinical decision support [14] - Future plans include expanding data services and operational management through clinical specialty databases and intelligent inspection platforms [14]